Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)

Status Recruiting

Clinical Trial Summary

Background:

Type II diabetes is a disease that affects more than 246 million people worldwide. Most importantly, one of the complications of type II diabetes is kidney damage and this has lead to many patients seeking hemodialysis treatment, a type of kidney replacement therapy. However, during hemodialysis treatment, many patients are greatly at risk for having their blood sugar drop below normal and this can lead to neurological problems. Also, it has been reported that hemodialysis patients who have poorer control of blood glucose levels are at risk to developing heart problems. It has been shown that adding 5.5 mmol/L of glucose in the hemodialysis treatment can reduce the chances of having an abnormal decrease in blood glucose levels. Currently, some institutions use 10 mmol/L of glucose (instead of 5.5 mmol/L) in the hemodialysis treatment, however, there is little documented support to justify for this action.

Objective:

The investigators are would like to explore the effects of use of 10 mmol/L of glucose in hemodialysis treatment and to determine if it worsens control of blood glucose levels, both during the treatment sessions and over the long term in type II diabetes patients. Also, patients on hemodialysis are prone to infection, so we will also observe if there is any change in infection rate among these patients with increased glucose in the treatment.

Methods:

The study will consist of 40 patients who will be randomly split into 2 groups. One group will be treated with 5.5 mmol/L glucose in the hemodialysis treatment and the other group will have 10 mmol/L glucose in the treatment. During the hemodialysis treatment, patient blood glucose will be measured at set intervals to check for any acute drops in glucose levels. Also, to assess long-term control of blood glucose levels, each patient will have 2 blood tests, one at the start and another at the end of the experiment. Signs of infection will be checked at the start of each session. Each patient will remain in their group for the duration of the study, which is 12 weeks.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01359904
Study type	Interventional
Source	McGill University Health Center
Contact	Jeffrey How, MD
Phone	5149341934
Email	jeffrey.how2@mail.mcgill.ca
Status	Recruiting
Phase	Phase 3
Start date	May 2011
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting	`NCT04954313` - Baseline Oral Health Study: UnCoVer the Connections to General Health	Phase 4
Not yet recruiting	`NCT06437782` - Exploration of Health Literacy in Diabetes in Reunion Island and France
Completed	`NCT01354925` - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan	Phase 4
Completed	`NCT01206725` - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction	N/A
Completed	`NCT00997282` - A Study of OPC-262 in Patients With Type 2 Diabetes	Phase 2/Phase 3
Completed	`NCT00637546` - Gait and Balance of Diabetes Type 2 Patients	Phase 2/Phase 3
Completed	`NCT00464880` - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy	Phase 1/Phase 2
Withdrawn	`NCT02057497` - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms	N/A
Active, not recruiting	`NCT05014204` - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes	N/A
Recruiting	`NCT03662217` - Personalized Nutrition for Diabetes Type 2	N/A
Completed	`NCT04276051` - Cryovagotomy Diabetes Trial	N/A
Completed	`NCT02569684` - Effects of Prebiotics on GLP-1 in Type 2 Diabetes	N/A
Active, not recruiting	`NCT01933529` - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)	Phase 2
Terminated	`NCT01722474` - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.	N/A
Completed	`NCT00977262` - Postprandial Inflammation and Fatty Acids	N/A
Completed	`NCT00518427` - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine	Phase 4
Recruiting	`NCT05378620` - Project Dulce for Filipino-Americans With Type 2 Diabetes	N/A
Recruiting	`NCT03834207` - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy	N/A
Active, not recruiting	`NCT05228067` - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.